Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Subcutaneous Nomlabofusp in Friedreich’s Ataxia
2025-521628-31-00Phase 3Authorised
- Sponsor
- Larimar Therapeutics
- Start
- Apr 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in Friedreich ataxia (FA) comparing Nomlabofusp with Placebo to Nomlabofusp (2 arms). Planned start Apr 2026; status: authorised.
02
Drugs
nomlabofusp
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2025-521628-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521628-31-00.